Differentiation therapy of myelodysplastic syndromes: fact or fiction?
Santini
V
V
Department of Haematology, University of Florence, Firenze, Italy.
Ferrini
P R
PR
D000081:Acetamides / Q000627:therapeutic use; D004999:Amifostine / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001120:Arginine / Q000627:therapeutic use; D001374:Azacitidine / Q000627:therapeutic use; D002087:Butyrates / Q000627:therapeutic use; D002762:Cholecalciferol / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D006248:Harringtonines / Q000627:therapeutic use; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use; D006418:Heme / Q000627:therapeutic use; D000077863:Homoharringtonine; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D009190:Myelodysplastic Syndromes / Q000628:therapy*; D012176:Retinoids / Q000627:therapeutic use
D000081:Acetamides; D000970:Antineoplastic Agents; D002087:Butyrates; D006248:Harringtonines; D016298:Hematopoietic Cell Growth Factors; D012176:Retinoids; D003561:Cytarabine; D002762:Cholecalciferol; D006418:Heme; D000077863:Homoharringtonine; D007372:Interferons; D001120:Arginine; C014026:hexamethylene bisacetamide; D004999:Amifostine; D001374:Azacitidine; C048849:heme arginate